Spago Nanomedical: Strengthened Management - Redeye

Redeye endorses Spago appointing Paul Hargreaves as Chief Development Officer as the company’s Tumorad project approaches the clinical stage. We are encouraged by his vast experience in clinical development, spanning nearly 30 years. Today’s news reinforces our conviction in Spago executing its clinical development plans for both its SpagoPix and Tumorad projects.

Länk till analysen i sin helhet: https://www.redeye.se/research/817993/spago-nanomedical-strengthened-management?utm_source=finwire&utm_medium=RSS